Esperion Therapeutics, Inc. consummated a merger-based acquisition by Essence Parent Inc. on July 13, 2026, for approximately $1.1 billion in cash, plus the issuance of Contingent Value Rights (CVRs). Shareholders of common stock were entitled to receive $3.16 per share in cash and one CVR per share, representing a right to participate in contingent cash payments of up to $0.1 billion in the aggregate. The company's common stock will be delisted from the Nasdaq Stock Market LLC. Esperion Therapeutics, Inc. is a biopharmaceutical company focused on cardiovascular disease management.

At a special meeting held on July 8, 2026, Esperion Therapeutics stockholders approved the Merger Agreement dated May 1, 2026, between the Company, Essence Parent Inc., and Essence MergerCo Inc. The approval allows MergerCo to merge with the Company, resulting in the Company becoming a wholly owned subsidiary of Essence Parent Inc. A quorum was established by 158,573,615 shares, representing 61.53% of the 257,693,347 issued and outstanding shares. Additionally, stockholders approved an advisory, non-binding proposal regarding executive compensation related to the merger. Esperion Therapeutics is a biopharmaceutical company focused on developing medicines for cardiovascular disease.

Esperion Therapeutics, Inc. filed an 8-K/A to provide the required financial statements and pro forma financial information regarding its acquisition of Corstasis Therapeutics Inc. The filing includes audited consolidated financial statements for Corstasis for the years 2024 and 2025, along with unaudited pro forma condensed combined balance sheet and statements of earnings for the fiscal year 2025. Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular-related therapies.

Esperion Therapeutics, Inc. announced that the Hart-Scott-Rodino Antitrust Improvements Act waiting period expired on June 15, 2026, regarding its merger with Essence Parent Inc. The transaction remains subject to other closing conditions, including stockholder approval at a special meeting scheduled for July 8, 2026. Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines.

Esperion Therapeutics, Inc. announced that the Bundeskartellamt has cleared its proposed merger with Essence Parent Inc., an affiliate of ArchiMed SAS. The merger, which would make Esperion a wholly-owned subsidiary of Parent, remains subject to closing conditions including Hart-Scott-Rodino Antitrust Improvement Act waiting periods and stockholder approval at a special meeting scheduled for July 8, 2026. Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cardiovascular disease.